JS019 / Shanghai Junshi Biosci, Beijing Eirene, Suzhou Kebo Ruijun Bio - LARVOL DELTA

Proof-of-concept study of the CD39-blocking antibody JS019 in eosinophilic-associated disorders (ASH 2025) - "Eligible participants wereadults with eosinophil counts >1.5 × 10⁹/L accompanied by organ involvement, refractory or relapsedafter prior treatment, and on stable glucocorticoid therapy (prednisone ≥10 mg/day or equivalent) for ≥1month prior to screening. No Grade 4 events or dose-limiting toxicities were observed.ConclusionsThis proof-of-concept study demonstrates that CD39 blockade with JS019 induces rapid, selective andsustained eosinophil suppression in patients with eosinophilic-associated disorders, accompanied byearly clinical improvements and a favorable safety profile. These results support further clinicaldevelopment of JS019 in type 2 inflammation beyond oncology."

Atopic Dermatitis • Dermatology • Eosinophilia • Hematological Malignancies • Hypereosinophilic Syndrome • Hypotension • Immunology • ENTPD1

A Clinical Study to Evaluate the Safety, Tolerability,JS019 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=72 | Recruiting | Sponsor: Suzhou Kebo Ruijun Biotechnology Co., Ltd

New P1 trial • Oncology • Solid Tumor • ENTPD1

A Phase 1 Study to Evaluate JS019 in Advanced Solid Tumors or Lymphomas (clinicaltrials.gov) - P1 | N=172 | Recruiting | Sponsor: Suzhou Kebo Ruijun Biotechnology Co., Ltd

New P1 trial • Hematological Malignancies • Lymphoma • Oncology • Solid Tumor • ENTPD1